Zevra Therapeutics
ZVRA
157 hedge funds and large institutions have $642M invested in Zevra Therapeutics in 2026 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 64 increasing their positions, 41 reducing their positions, and 17 closing their positions.
71% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 17
67% more capital invested
Capital invested by funds: $385M → $642M (+$257M)
56% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 41
6% more funds holding
Funds holding: 148 → 157 (+9)
5.45% more ownership
Funds ownership: 70.37% → 75.83% (+5.5%)
24% less call options, than puts
Call options by funds: $23.9M | Put options by funds: $31.6M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$18.9M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$14.8M |
| 3 |
BlackRock
New York
|
+$7.25M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$6.64M |
| 5 |
D.E. Shaw & Co
New York
|
+$5.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$11.2M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$10.8M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$8.05M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$6.83M |
| 5 |
Millennium Management
New York
|
-$5.56M |
ZVRA Hedge Fund Activity: Q2 2026 in Review
157 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q2 2026, worth a combined $642M — up 67% from $385M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new ZVRA positions and 17 closed out — a net gain of 12 holders — while 64 added to existing stakes and 41 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $18.9M. The largest seller was AIGH Capital Management, exiting entirely with an estimated $11.2M sold.
- 157 institutional investors held Zevra Therapeutics (ZVRA) as of Q2 2026, up from 148 in Q1 2026.
- Funds reported $642M of Zevra Therapeutics stock for Q2 2026, up 67% quarter-over-quarter.
- 29 funds opened new Zevra Therapeutics positions in Q2 2026 and 17 closed out, a net change of +12 holders.
- The largest Zevra Therapeutics buyer in Q2 2026 was Fidelity Investments, an estimated $18.9M added.
- The largest Zevra Therapeutics seller in Q2 2026 was AIGH Capital Management, an estimated $11.2M sold.
Based on aggregated 13F filings for Q2 2026.